Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 243

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 243
---
 of detailed trade and other receivables
 
                                      2024                 2023       
----------------------------------------------------------------------
                                                       December 31,   
                                           2024                2023   
                                                   $                 $
Trade accounts receivable, net            1,884                 126   
Value added tax                             383                   -   
Other receivables                            90                 164   
Total                                     2,357                 290   

9.   Inventories
----------------
 
The Company had the following inventories at the end of each reporting period:
  Schedule of inventories
 
                        2024                   2023        
-----------------------------------------------------------
                                            December 31,   
                             2024                   2023   
                                     $                    $
Raw materials                 737                    878   
Work in progress            1,655                  2,587   
Finished goods                299                    544   
Inventories                 2,691                  4,009   
 
Inventories expensed to cost of goods sold during the year ended December 31, 2024, are $4,432 (2023 - $3,472 and 2022 - $5,344).
 
During the year ended December 31, 2024, the Company decreased the carrying value of inventory by $7 (2023 - $3 and 2022 - $18) primarily due to damaged or obsolete inventory. The write-down is included in cost of goods sold.
 

10.                Prepaid             
      expenses and other current assets
---------------------------------------
  Summary of prepaid expenses and other current assets
 
                                        2024                 2023       
------------------------------------------------------------------------
                                                         December 31,   
                                             2024                2023   
                                                     $                 $
Prepaid insurance                           1,700                  81   
Prepaid research and development              516                  97   
Other                                         210                 112   
Total                                       2,426                 290   

F-26
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 
11. Property and equipment
 
Components of the Company’s property and equipment are summarized below.
  Schedule of property and equipment
 
                                           Equipment Not Available for Use            Equipment             Office and Computer Equipment            Buildings              Leasehold Improvements              Total       
--------------------------------------------------------------------------------------------------------------------------------